Lysozyme in Pleural Effusions
To the Editor:
We read with considerable interest the report by Verea Hernando and colleagues' on the diagnostic value of determining the lysozyme (LZM) levels in serum and pleural fluid. The paper was in concordance with our own experience2 and confirmed the high sensitivity and specificity of the assay in discriminating tuberculous and nontuberculous effusions.
Pleural effusions associated with connective tissue diseases, ie, rheumatoid arthritis (BA), may pose diagnostic difficulties and the concentration of biochemical variables in the pleural fluid mav not be diagnostic. In 1982, Asseo et alt reported variable concentrations of LZM in rheumatoid pleural effusions. We wish to report certain important methodologic considerations when LZM assays are used for the study of pleural effusion associated with RA.
Nine patients with classic or definite RA (as defined by the criteria of the American Rheumatism Association) and pleural effusion were studied. Etiologic factors other than RA as the cause of pleural effusion were excluded by careful clinical examination and by biochemical, cytologic and bacteriologic analyses of pleural fluid.
LZM in serum and pleural fluid was measured using two methods.
Purified hen egg white LZM was used as a standard in the turbidimetric test (Testomar, Behring Institute, West Germany)4 and purified human LZM was used as a standard in the lysoplate method.' Table 1 shows that LZM assays using the two different methods (including LZM standards isolated from different species) give different results for the concentration of LZM. Most of the patients with RA had a normal concentration of LZM in serum. However, in these patients the pleural fluid concentration of LZM was 1.3 to 4.7 times (mean 2.5) higher than the serum levels when assayed with the turbidimetric method. With the lysoplate method, the pleural fluid-to-serum LZM ratio varied from 0.8 to 2.0 (mean 1.2). Noticeably, the ratio was increased in some patients with RA when LZM is assayed with the lysoplate method, but it is increased in all patients when determined with the turbidimetric method. When pleural fluid-to-serum LZM ratios were compared in patients with pleural effusions due to other causes (including SLE), this kind of difference was not observed ( Table 1 ).
The two most widely used assays for the determination of LZM are the so called turbidimetric and lysoplate methods. The differences in reference values in the two methods described have repeatedly been reported and are explained by the different relative rates of lytic activity by lysozymes from different sources (hen egg white and man) in the turbidimetric and lysoplate methods. Using these two methods, we obtained different values for the pleural fluid-to-serum LZM ratios (in which the significance of the different standards is excluded) only in patients with RA. It is possible that factors present in rheumatoid pleural effusions interact differently in the two assay systems. In the turbidimetric method, micrococci are lysed rapidly in suspension, whereas in the lysoplate method micrococci are lysed during a diffusion process in agarose with longterm incubation. Interestingly, a similar methodologic difference was pointed out in the correspondence concerning the differential diagnostic value of LZM determinations in ulcerative colitis and Crohn's disease.7 Another explanation for this discrepancy is that done; Tbc = tuberculosis; SLE = systemic lupus erythematosus; CHF = congestive heart failure; Nonspec = pleurisy of unknown etiology; in parenthesis = the number of patients studied. *Lysoplate data taken from ref 2. there are different LZM isoenzymes in man with different lytic activities in the two assay systems. These isoenzymes might be derived from different tissues, eg, leukocytes and cartilage, in patients with RA. Furthermore the presence of possible LZM inhibitors, (ie, circulating glycosaminoglycans) in RA8 may cause charge interactions with cationic LZM and subsequent interference, particularly in the lysoplate (diffusion) assay
We emphasize that these methodologic considerations must be recognized when LZM determinations of pleural fluid are used in the diagnostic procedures to discriminate between tuberculous and rheumatoid pleural effusions.
Charcot-Marie-Tooth Disease and Respiratory Failure
We would like to report our experience with a patient with Charcot-Marie-Tooth disease and respiratory failure. Our She had a 30-yr history of progressive bilateral foot and leg weakness, and had spent the last ten years in a wheelchair. In recent years she had become weak in the hands and arms. She had no previous history of pulmonary disease and had never smoked cigarettes. Examination revealed bilateral atrophic paralysis of gastrocnemius and peroneal muscles, and pes cavus deformities. Muscle atrophy and weakness were present in the intrinsic muscles of the hands. Both shoulders were weak, the trapezius muscles were ribbon-like, and the chest was moderately kyphoscoliotic. No deep tendon reflex was present. No fasciculations, cranial nerve abnormalities or peripheral nerve enlargement was present. Spontaneous tidal volume was 60 to 80 ml, vital capacity was 200 to 250 ml and minute ventilation was 1.5 to 2.0 L/min. Maximum negative inspiratory force she could generate varied from negative to 12 cm H2O and did not improve with correction of mild hypokalemia and hypophosphatemia, the only identified serum chemical perturbations. Thyroid function studies, aldolase, magnesium, anti-nuclear antibody, rheumatoid factor, and creatinine phosphokinase levels were
normal. An RPR test was non-reactive. Chest radiographic film showed reduced lung volume, subsegmental basal atelectasis and a calcified mitral annulus. Compensated mitral insufficiency was confirmed by physical examination and echocardiography Cerebrospinal fluid was benign. A computed tomogram of the head showed only mild cerebral atrophy Electromyographic and nerve conduction velocity studies of the lower extremities showed no motor response in the lower limbs and conduction velocities of 14 m/sec in the upper extremities. Her only son was examined and was found to have a significant peroneal atrophy, high arches and leg weakness.
A cousin was examined and found to have absent ankle jerks, peroneal weakness, atrophy of the hands, and conduction velocities of 27 ni/sec in the arms. Additional family history obtained revealed that the patients mother had reported hand atrophy Two siblings of the patient had high arches, gait disturbance and atrophy of the hands. Over four generations of the family are affected in a pattern of autosomal dominant inheritance. She could not be weaned from the respirator because of persistent hypoventilation and lived two years at home with positive pressure ventilation therapy before dying of urosepsis and cerebrovascular accident.
We believe this woman had Charcot-Marie-Tooth disease because of the progressive atrophic paralysis beginning in the feet, nerve conduction velocity studies compatible with a chronic demyelinating neuropathy, absence of deep tendon reflexes, and findings in her family typical of this disease. We were not able to study this patients diaphragm function as Chan et al were able to do with their patients. We cannot prove that Charcot-Marie-Tooth disease directly involved any of her respiratory muscles. Kyphoscoliosis was no doubt a factor in this woman's hypoventilation, but our judgment is that her respiratory failure far exceeded that which might be expected with her degree of scoliosis. We would like simply to draw further attention to a possible cause-effect relationship of Charcot-MarieTooth disease and respiratory failure so that more observation might be made.
